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Objective: The present investigation was aimed at preparation and evaluation of mouth dissolving films (MDFs) of Ramipril to enhance patient 
convenience, compliance and to improve bioavailability.  
Methods: MDFs with 0.5% w/w Ramipril were prepared by a solvent casting method using a wet film applicator. The effects of film formers, 
wetting/solubilizing, saliva stimulating agents and film modifiers on the physicomechanical and in vitro Ramipril release from MDFs were evaluated.  
Results: The MDFs prepared were transparent, smooth and showed no re-crystallization upon storage. MDFs casted with hydroxypropyl 
methylcellulose (HPMC) E3 as film former and polyethylene glycol (PEG-400) as plasticizer showed superior Ramipril release rates and good 
physicomechanical properties when compared to MDFs with E5 and E15 as film formers. HPMC E3 MDFs with polyvinyl pyrrolidone K30 (PVP K30) 
and sodium lauryl sulphate (SLS) gave superior drug release properties than MDFs without PVP K30 and SLS. The HPMC E3 MDFs with citric acid 
(CA) as saliva stimulating and xylitol as soothing agent gave significantly superior in vitro drug release than the MDFs without CA and xylitol. 
Release kinetics data reveals diffusion as a drug release mechanism. 
Conclusion: From the obtained results, it can be concluded that the administration of Ramipril as MDF may provide a quick onset of action with 
enhanced oral bioavailability and therapeutic efficacy. 
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Hypertension is a chronic medical condition involving the elevated 
blood pressure levels. The delayed treatment of hypertension can 
lead to several other fatal disorders like congestive heart failure, 
kidney failure, stroke, etc. Moreover, the hypertension can occur in 
sudden, severe and acute attacks requiring immediate treatment [1]. 
Most of the anti-hypertensives are available in the oral or parenteral 
dosage forms, which have certain limitations such as swallowing and 
chocking difficulties, delayed onset of action, first pass metabolism, 
the requirement of skilled personnel and pain during delivery. These 
limitations and a need for the quicker onset of action with better 
patient acceptability has paved the way for the development of mouth 
dissolving films (MDFs) as an alternative to other dosage forms [2]. 
The MDFs are a very thin polymeric strip, which get hydrated instantly 
by saliva when placed on a patients tongue and then disintegrates 
and/or dissolves to release the medication within the pre-oral cavity 
[3]. The oral cavity composed of striated squamous epithelia with very 
thin membranes and fine capillary network provides 4-4000 times 
greater absorption than other parts of skin [4]. 
Ramipril is a new generation anti-hypertensive drug and is an 
angiotensin-converting enzyme (ACE) inhibitor. Ramipril is a 
prodrug/precursor which is converted into active metabolite 
‘Ramiprilat’ in liver by carboxylesterase. Ramipril 
inhibits the actions of ACE lowering the production of angiotensin II 
[6]. This results in relaxation of arteriole smooth muscle leading to a 
decrease in total peripheral resistance, reducing blood pressure. 
Ramipril undergoes first-pass metabolism and has an oral 
bioavailability of about 28-30% [7]. Presently, Ramipril is marketed 
in the form of oral disintegrating tablets (ALTACE
The drug is directly 
absorbed into the systemic circulation which by-passes the first pass 
metabolism, improving the bioavailability of the drug [5]. 
®) and immediate 
release tablets (CARDACE®
Few reports were published on formulation and evaluation of 
ramipril oral disintegrating, immediate release tablets, buccal 
patches and films. In most of the works reported so far, MDFs were 
prepared in petri plates, moulds etc. and the films were dried at 40-
45 °C overnight and this procedure may not result in uniformity of 
thickness and drug content and thereby, vary the drug release rates 
[7-12]. Moreover, no works on the influence of formulation variables 
like film thickness, polymer viscosities, surfactants and saliva 
stimulating agents were reported. Also, the reported works were not 
evaluated thoroughly for the drug loading effect on the re-
crystallization and characterization using photographic, Fourier-
transform infrared spectroscopy studies (FTIR), etc. By considering 
all the above facts, the present investigation was aimed to prepare 
MDFs using wet film applicator, an industrially scalable technique 
and evaluate them systematically. 
).  
MATERIALS AND METHODS 
Materials 
Ramipril was obtained from Mylan Laboratories, Hyderabad. 
Hydroxypropyl methyl cellulose (HPMC E3, E5 and E15) samples 
were obtained from Colorcon Asia Ltd., India. Ethanol, polyvinyl 
pyrrolidone (PVP) K30, sodium lauryl sulphate (SLS) and citric acid 
(CA) were purchased from Loba Chemie, Mumbai. Pineapple flavour 
was obtained from Darwin laboratories, Vijayawada. Xylitol was 
obtained from Rouquette Laboratories, France. All the ingredients of 
analytical grade were used. 
Methods 
Preparation of artificial saliva 
Artificial saliva was prepared by dissolving 0.844 g of sodium 
chloride, 1.2 g of potassium chloride, 0.193 g of calcium chloride 
dehydrate, 0.111 g of magnesium chloride hexahydrate and 0.342 g 
of potassium phosphate dibasic one by one in 500 ml of distilled 
water and then the final volume was made up to 1000 ml using the 
distilled water. The pH was adjusted with 0.1N HCl to 5.7 [13]. 
Preparation of ramipril MDFs 
Ramipril MDFs were prepared as per the formula is given in table 1 
by using the solvent casting method to a batch size of 5 g. Ramipril 
was dissolved in a mixture of solvents (water and ethanol) in a 
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beaker and other ingredients were added one by one and finally the 
polymer was added and mixed thoroughly. The mixture was 
sonicated for 5 min to remove entrapped air bubbles and casted on a 
glass plate with wet film applicator set at 30 mil (750 µm) and the 
film was dried at 45 °C for 60 min in hot air oven. Then the dried 
films were peeled off from the glass plate, cut into appropriate sizes 
and stored in desiccators until use.  
FTIR studies  
Samples were analysed using an Attenuated Total Reflectance 
(ATR)-FTIR spectrometer (Bruker, Germany). ATR spectra were 
measured over the wave number range of 4000-500 cm-1at a 
resolution of 1.0 cm-1
Evaluation parameters for ramipril MDFs 
. The powder or film sample was placed onto 
the ATR crystal and the sample spectrum was collected. 
Morphological properties 
Morphological properties of ramipril MDFs were tested by visual 
observations for a period of 6 mo. All the MDFs prepared were 
packed in aluminium foil pouches and stored at room temperature 
(25±3 °C) with the relative humidity of approximately 65±5%. 
Changes inhomogeneity, colour, transparency and surface of MDFs 
were observed once in a month for 6 mo’s duration [17]. 
Thickness 
The thickness of the film was measured using a screw gauge with a 
range of 0-10 mm and revolution 0.001 mm. Anvil of the thickness 
gauge was turned and the film was inserted after making sure that 
the pointer was set to zero. The film was held on the anvil and the 
reading on the dial was noted down. The estimations were carried 
out in triplicate [18]. 
Drug content 
The amount of ramipril in the MDFs was estimated by dissolving 1 
cm2
Variation of mass 
films in a 10 ml volumetric flask containing 5 ml of artificial 
saliva and then the final volume was made up with the same [19]. 
The samples were then suitably diluted with artificial saliva and 
analysed for ramipril content by UV spectrophotometric method 
measured at 230 nm (UV Spectrophotometer, UV 1800 SHIMADZU). 
The estimations were carried out in triplicate. 
Mass of 1 cm2
In vitro disintegration studies 
 film from different batches of the formulations was 
noted on an electronic balance. The estimations were carried out in 
triplicate [17]. 
In vitro disintegration time of MDFs was studied visually using two 
independent methods namely drop and petri dish methods. For both 
the methods, only a small amount of medium was required, so that 
natural conditions are simulated. 
Drop method  
In this method, the films were placed on a glass slide and placed 
planar on a petridish. One drop of distilled water was dropped by a 
pipette onto the oral films. The time until the film dissolves and 
forms a hole in the film was measured. The estimations were carried 
out in triplicate [18]. 
Petri dish method  
In this method, 2 ml of distilled water was placed in a petri-dish and 
a film of 2x2 cm2
Tensile strength 
 was placed on the surface of the water and the time 
required to dissolve the film completely was measured. The 
estimations were carried out in triplicate [18]. 
Tensile strength is the maximum stress applied to a point at which 
the film specimen breaks [14]. It is calculated by the load at rupture 
divided by the cross-sectional area of the film as given below:  
Tensile strength = Load at Failure × 100
Film Thickness x Film Width
 
Tensile strength of MDFs was measured using Mini Tech 
Tensiometer-UTM9051 (Dak Systems Inc., Mumbai, India) fitted 
with a load cell of 500 N (50 kg) capacity and the data was collected 
using Test Bench II software [17-19]. Samples of appropriate film 
thickness with fixed dimensions (LxW-10x2 cm) were fixed between 
pneumatic grips with a gauge dimension of 3 cm length between 
grips. All the dimensions were entered into the software to calculate 
the cross-sectional area. The film was carefully placed in between 
the pneumatic grips avoiding any loose folds. An instrument was 
operated at a speed of 5 mm/min until the film breaks. Percent 
elongation data was also computed from the software for each 
sample. Whole experiment was carried out in triplicate. 
Percent elongation  
When stress is applied the film sample stretches and is referred to as 
strain. Strain is basically the deformation of the film divided by the 
original dimension of the film. Generally, elongation of the film increases 
as the plasticizer concentration increases [15]. Percentage elongation 
was calculated by measuring the increase in the length of the film after 
tensile strength measurement by using the following formula:  
Percent Elongation =[L−Lo] X 100
Lo
 
Where, L = Final length, L0
Folding endurance 
 = initial length. The estimations were 
carried out in triplicate. 
Folding endurance is determined by repeated folding of the film at 
the same place till the film breaks. This gives an indication of the 
brittleness of the film. The number of times the film is folded 
without breaking is computed as the folding endurance value [16]. 
The estimations were carried out in triplicate. 
In vitro drug release studies 
The in vitro drug release studies were conducted using 500 ml of 
artificial saliva as dissolution medium with modified USP Type V 
dissolution rate testing apparatus. A temperature of 37 °C and 50 rpm 
were maintained. Each film of appropriate size (3 x 2.6 cm2) equivalent 
to 5 mg dose was cut and placed on a watch glass covered with nylon 
wire mesh. The watch glass was then dropped into dissolution flask. 5 ml 
samples were withdrawn at predetermined time intervals 5, 10, 20, 30, 
40, 50, 60, 80, 100, 120, 180, 240, 300, 360 s and every time replaced 
with 5 ml of fresh dissolution medium. The samples were analysed by 
measuring absorbance at 230 nm. The drug release experiments were 
conducted in triplicate [17]. 
Stability studies 
Stability studies were carried out on F6 (containing 0.5 % ramipril, 
7.5 % HPMC E3, 0.04 % PVP K30, 0.25 % CA and 0.5 % xylitol). MDFs 
were packed in aluminium pouches, sealed and stored at 40 
°C/75±5% RH for 6 mo. The appearance, weight and drug content 
properties of the MDFs were examined. 
Statistical analysis 
Results of experimental data were subjected to one-way ANOVA 
(using Fisher’s LSD Post HOC test) using SYSTAT software (SYSTAT 
Software Inc., San Jose, USA). Results with ‘p’ value of less than 0.05 
(P<0.05) were considered as significant variance. 
RESULTS AND DISCUSSION 
Preparation and physical characterization of RPL MDFs 
In the present investigation, the MDFs were prepared using a wet 
film applicator which is also a commercially scalable technique. 
Initially placebo MDFs were prepared with different polymers like 
HPMC (E3, E5, E15), methylcellulose, sodium carboxymethyl 
cellulose (Na CMC) and sodium alginate using PEG-400 as the 
plasticizer and observed for film forming capacity and appearance. 
From the trails made and results obtained, HPMC E3, E5, E15 and Na 
CMC were selected for further development. However, films 
prepared with NaCMC were not separable from glass plate upon 
drug loading. Hence HPMC polymers with different viscosity grades 
were selected for further studies. Ramipril of 0.5 % w/w (25 mg) 
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was added to the MDFs and the films were casted at 30 mil 
thickness. The obtained MDFs were found to be smooth, transparent 
and showed no re-crystallization upon storage. Different ramipril 
MDFs were prepared at 0.5 % w/w ramipril load and all the 
formulae were given in table 1. A 5 g batch size of formulations gave 
approximately 96 cm2
 
 film area. 
Table 1: Composition of different ramipril MDFs 
Ingredients(mg) Formulae (5 g batch size) 
F1 F2 F3 F4 F5 F6 
Ramipril 25 25 25 25 25 25 
HPMC E3 375 - - 375 375 375 
HPMC E5 - 375 - - - - 
HPMC E15 - - 375 - - - 
PEG 400 25 * 25 25 25 25 25 
PVP K30 - - - 2 - 2 
SLS - - - - 2 - 
Water* 1785 1785 1785 1785 1785 1785 
Ethanol 2745 * 2775 2775 2773 2773 2750.5 
Citric acid - - - - - 12.5 
Xylitol 25 25 25 25 25 25 
Colouring agent 10 10 10 10 10 10 
Flavouring Agent 10 10 10 10 10 10 
Total Weight 5000 5000 5000 5000 5000 5000 
*All the amounts were taken based up on their density. [MDFs: Mouth dissolving films, HPMC: Hydroxy propyl methyl cellulose, PEG: Polyethylene 
glycol, PVP: Polyvinylpyrrolidone, SLS: Sodium Lauryl sulphate] 
 
FTIR analysis 
To probe the potential interactions between ramipril and the 
excipients of MDFs, an FTIR studies were conducted. Four 
characteristic peaks at 1740.58 cm-1(aliphatic C=O stretching), 
1648.48 cm-1(C=C stretching), 1183.21 cm-1(C-N stretching), 778.00 
cm-1
  
(=C-H bending) were observed. These characteristic peaks of 
ramipril were all retained in the MDFs. The FTIR spectrum is shown 
in fig. 1. These results indicate that there is no interaction between 
ramipril and excipients in MDFs. 
 
Fig. 1: FTIR spectrum overlay of pure ramipril ( ), F4 ( ), F6 ( ) 
 
 
Fig. 2: Photographs of ramipril MDFs (Mouth dissolving films) 
 
Morphological properties 
Ramipril MDFs were visually tested for homogeneity, transparency, 
colour and smoothness. MDFs formulated with 0.5 % w/w ramipril 
were transparent with no re-crystallization. The photographs were 
shown in fig. 2. 
Thickness 
The thickness was measured with screw gauge at different places of 
MDFs in order to evaluate the reproducibility of preparation methods 
[17-19]. Around 90% of wet film thickness was lost during drying. The 
results were given in table 2 and good uniformity of thickness was 
observed. MDFs casted at 30 mil thickness containing PVP and SLS 
showed higher thickness values compared to the other formulations.  
Drug content 
Films of 1 cm2 were cut from different areas (n=3) of the whole film 
and ramipril content was estimated. The results were given in table 
2. The results indicated a good uniformity of ramipril within the film, 
overall good solubilization of ramipril in MDFs was observed. MDFs 
were casted at 30 mil thickness. 
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Table 2: Physicomechanical properties of different ramipril MDFs 




Disintegration time (sec) # 
Drop method Petri dish method* * 
F1 0.23±0.019 2.53±0.11 75.00±5.47 21.33±0.58 27.66±0.58 
F2 0.31±0.005 2.73±0.05 78.33±4.08 26.67±1.15 34.33±1.15 
F3 0.29±0.020 2.96±0.11 86.66±5.16 34.67±1.53 41.00±1.53 
F4 0.35±0.011 2.66±0.05 78.33±4.08 18.67±0.58 24.66±0.28 
F5 0.38±0.005 2.60±0.10 76.66±5.16 19.33±0.58 25.33±0.58 
F6 0.30±0.025 2.76±0.05 78.33±4.08 14.67±0.58 21.00±0.58 
All the values are expressed as mean±SD, * n=3 and # n=6. MDFs: Mouth dissolving films 
 
 




Fig. 4: Comparative tensile strength profiles of all the ramipril film formulations 
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Table 3: Physicomechanical properties of different ramipril MDFs 
Formulations % Elongation Folding endurance*  * 
F1 5.22±0.09 78±2 
F2 5.81±0.02 86±3 
F3 7.41±0.13 98±2 
F4 5.83±0.04 86±4 
F5 5.79±0.07 84±3 
F6 5.92±0.23 83±2 
*All the values are expressed as mean±SD (n=3). MDFs: Mouth dissolving films 
 
Variation of mass 
Films of 1 cm2
In vitro disintegration studies 
were cut from different batches and weighed. The 
results are given in table 2. Same mass of film was obtained with 
three batches of films indicating good reproducibility of preparation 
method and formulation. 
The results of the disintegration time are given in table 2. The results 
indicated that HPMC E3 formulations disintegrated faster than the 
E5, E15 which is due to low viscosity of E3 polymer compared to E5 
and E15. The MDFs with PVP disintegrated faster than the MDFs 
with and without PVP and SLS. The MDFs with CA disintegrated 
faster than the other MDF formulations. The images of MDF 
disintegration by drop and petri dish methods are shown in fig. 3. 
Tensile strength and % elongation  
MDFs should possess moderate tensile strength and high % 
elongation. The results revealed that MDFs containing PVP and SLS 
showed moderate tensile strength. The results were given in table 
3and shown in fig. 4. 
Folding endurance 
MDFs prepared with PVP and SLS showed high folding endurance 
values compared to other E3 formulations. The results were given in 
table 3. 
In vitro drug release studies 
In the present investigation, in vitro, drug release studies of MDFs 
were carried out using USP Type-V Dissolution Rate Testing 
Apparatus. 500 ml of artificial saliva was used as dissolution 
medium in order to mimic the in vivo conditions. The in vitro drug 
release profiles of ramipril MDFs are shown in fig. 5. 
MDFs of F1, F2 and F3 formulations were prepared with HPMC E3, E5 
and E15. The cumulative percent of ramipril released at the end of 5 s 
is 13.44±9.33, 8.64±1.96 and 3.64±1.75 for F1, F2 and F3 respectively. 
Complete ramipril release was obtained at 120 s, 240 s and 600 s for 
F1, F2 and F3 formulations respectively. From the results obtained, it 
was observed that MDFs with HPMC E3 showed significantly superior 
ramipril release when compared to MDFs containing E5 and E15. This 
may be due to the low viscosity of HPMC E3 polymer. 
HPMC E3 was selected as the film former in the further studies 
because of its superior physicomechanical and drug release 
characteristics. The effect of solubilising and/or wetting agents on 
ramipril release rates was also studied. PVP K30 and SLS were 
added to formulations at 0.04 % w/w level. The cumulative percent 
of ramipril released at the end of 5 s is 18.62±4.99 and 11.64±5.19 
for F4 and F5 respectively. A complete ramipril release were 
obtained at 80 s and 100 s for F4 and F5 formulations respectively. 
The formulations containing SLS and PVP K30 gave significantly 
superior drug release profiles when compared to the formulations 
without PVP K30 and SLS. MDF formulations with PVP K30 gave 
superior drug release properties when compared to SLS formulations. 
The MDF containing PVP K30 i.e. F4 formulation was selected for 
further studies because of it superior ramipril release profile. 
In the further studies, the effect of saliva stimulating and soothing 
agents on the ramipril release was studied. CA and xylitol were 
added at 0.25 % and 0.5 % w/w levels respectively to the 
formulation. A cumulative percent of 41.53±0.03 was obtained at the 
end of 5 s and the complete release of ramipril from the formulation 
was obtained at 60 s. The formulation containing CA and xylitol gave 
significantly superior drug release when compared to the 
formulation without CA and xylitol.  
Overall, the F6 formulation (0.5 % w/w ramipril load, 7.5 % HPMC 
E3, 0.04 % PVP K30, 0.25 % CA and 0.5% xylitol) was optimized as 
the best formulation because of its superior ramipril release profile 
and physicomechanical properties. 
Drug release kinetics  
To better understand the release profiles obtained with ramipril 
MDFs formulations, the drug release data obtained at different time 
points was fitted into kinetic models such as First order [20] and 
Higuchi plots [21]. The first order release rate constant ‘k’ (sec-1) 
values and correlation coefficient (R2
When compared to F1, the ‘k’ values were lower for F2 and F3 
formulations. A 1.55 and 3.68 fold decrease in ‘k’ values was 
observed for F2 and F3 formulations respectively. 
) values were calculated from 
drug release data (0-60 s) for ramipril MDFs. 
When compared to F1, the ‘k’ values were significantly higher for F4 
and F5 formulations containing PVP K30 and SLS respectively. A 
1.39 and 1.06 fold increase in ‘k’ values for F5 and F6 formulations 
was observed when compared to F1 formulation. Overall, MDFs of 
ramipril with PVP K30 and SLS gave higher ‘k’ values when 
compared to MDFs of ramipril without PVP K30 and SLS.  
Among 6 formulations, the ‘k’ value was significantly (p<0.05) higher 
for F6 when compared to the other formulations. The Higuchi square 
root model of all MDFs showed higher correlation coefficient values 
(0.900-0.998) indicating diffusion as release mechanism [21].  
 
 
Fig. 5: Comparative in vitro ramipril release profiles of MDF 
formulations (mean±SD; n=3). MDFs: Mouth dissolving films 
 
Stability studies 
Stability studies were carried out for F6 formulation containing 
HPMC E3, PVP K30 and CA. MDFs were stored at 40 °C with relative 
humidity of approximately 75±5 % for 6 mo. The appearance, weight 
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variation and drug content of the MDFs were examined. The 
appearance of MDFs remained unchanged throughout the studies 
and no re-crystallization was observed. There is no statistically 
significant change observed in the weight of MDFs. F6 formulation 
showed 94-102% of ramipril content after 6 mo, indicating that the 
ramipril was stable in MDFs. 
CONCLUSION 
From this investigation, it can be concluded that ramipril can be 
successfully formulated into MDFs. The film properties and drug 
release rates can be affected by the formulation variables such as 
polymer viscosities, wetting/solubilizing agents and saliva 
stimulating agents. The utilization of wet film applicator resulted in 
batch to batch reproducibility of different physicomechanical 
properties for ramipril MDFs. MDFs formulation F6 was subjected to 
stability studies and no change in appearance, weight and drug 
content was observed indicating that the ramipril was stable in the 
formulations. Formulation F6 containing 7.5 % w/w HPMC E3, 0.5 % 
w/w PEG-400, 0.04 % w/w PVP K30 and 0.25% CA showed superior 
physicomechanical and ramipril release rate compared to remaining 
formulations and was optimized as the best formulation. The 
administration of ramipril as MDFs may provide quick onset of 
action with enhanced oral bioavailability and therapeutic efficacy 
when compared to current marketed formulations like immediate 
release (IR) and orally disintegrating tablets (ODT’s) etc. 
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